ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; February 2021.
McMurray JJV, Packer M,Desai AS, et al. Baseline characteristics and treatment ofpatients in prospective comparison of ARNI with ACEI to determine impact onglobal mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014;16(7):817-25.
 Solomon SD, McMurray JJV, Anand IS, etal. Angiotensin-neprilysin inhibition in heart failure with preserved ejectionfraction. N Engl J Med.2019;381:1609-1620.
 Sanjiv J. Shah, et al. Angiotensin receptor neprilysin inhibition compared with individualized medical therapy for comorbidities in patients with heart failure and preserved ejection fraction - the PARALLAX trial. ESC Virtual Congress 2020 – Clinical Trials Hotline Session.
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee J Am Coll Cardiol. 2021 Feb 16;77(6):772-810.